Dangl et al.: "Abstract 5505: Synergistic anticancer activity of clinical stage, non-genotoxic apoptosis inducing agents RG7388 (MDM2 antagonist) and ABT-199 (GDC-0199, BCL2 inhibitor) in p53 wild-type AML tumor models", AACR Annual Meeting 2014 , April 2014 (2014-04), XP002759669, Retrieved from the Internet: URL:http://cancerres.aacrjournals.org/cont ent/74/19_Supplement/5505 [retrieved on 2016-07-08] (B1)

Flinn et al.: "4687 Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia", 56th ASH Annual Meeting and Exposition , December 2014 (2014-12), XP002759666, Retrieved from the Internet: URL:https://ash.confex.com/ash/2014/webpro gram/Paper75779.html [retrieved on 2016-07-08] (B1)

Herting et al.: "1780 Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity", 56th ASH Annual Meeting and Exposition , December 2014 (2014-12), XP002759668, Retrieved from the Internet: URL:https://ash.confex.com/ash/2014/webpro gram/Paper67783.html [retrieved on 2016-07-08] (B1)

WO-A1-2012/080389 (B1)

Ma et al.: "ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.", 2014 ASCO Annual Meeting , June 2014 (2014-06), XP002759665, Retrieved from the Internet: URL:http://meetinglibrary.asco.org/content /132375-144 [retrieved on 2016-07-08] (B1)

Roberts et al.: "325 Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)", 56th ASH Annual Meeting and Exposition , December 2014 (2014-12), XP002759664, Retrieved from the Internet: URL:https://ash.confex.com/ash/2014/webpro gram/Paper71378.html [retrieved on 2016-07-07] (B1)

Rongqing et al.: "Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)", 56th Annual Meeting of the American-Society-of-Hematology , December 2014 (2014-12), XP002759670, Retrieved from the Internet: URL:www.bloodjournal.org/content/124/21/21 62 [retrieved on 2016-07-08] (B1)

Herting et al.: "3915 Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263", 52nd ASH Annual Meeting and Exposition , December 2010 (2010-12), XP002759667, Retrieved from the Internet: URL:https://ash.confex.com/ash/2010/webpro gram/Paper26413.html [retrieved on 2016-07-08] (B1)